A study has revealed that the Transcatheter mitral valve repair (TMVR) is safe, provides a durable decline in mitral regurgitation (MR), decreases rate of heart failure (HF) hospitalization, and enhances survival, quality of life, and functional capacity in patients with HF and moderate-to-severe or severe mitral regurgitation (MR) who remained symptomatic despite guideline-directed medical therapy (GDMT).
 |
| Photo: Heart Failure | InStyleHealth |
The researchers said, “Surviving patients who
crossed over to device treatment had a prognosis comparable to those originally
assigned to transcatheter therapy.”
The study covered a total of 614 HF patients with moderate-to-severe
or severe secondary mitral regurgitation (MR), who continued to be symptomatic
despite maximally tolerated GDMT, were randomized to TMVR plus GDMT or GDMT
alone. Heart failure (HF) hospitalizations through 24-mont-follow-up was the
fundamental endpoint. Patients under study were monitored for 36 months.
Heart failure hospitalizations annualized rate per patient-per-year
was lower in the TMVR group comparative to the GMDT alone group (35.5% vs 68.8%).
Mortality rate was also found to be lower in the device group in comparison to
the control group (42.8% vs 55.5%). Furthermore, patients who underwent TMVR had
endured 3-year improvements in MR severity, quality of life measures, and
functional capacity.
HF hospitalization’s subsequent composite mortality
rate also reduced in 58 patients assigned to GDMT alone who crossed over and
were treated with TMVR as opposed to those who sustained on GDMT alone. For complete
details of the study, click here.
Source: J Am Coll Cardiol 2021;77:1029-1040